Who to call at Traws Pharma, Inc., and when
Fundz watches for the moments Traws Pharma, Inc. starts buying, and tells you who to reach.
- An alert the day Traws Pharma, Inc. raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Traws Pharma, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Traws Pharma, Inc.. With Fundz connected, it knows.
Traws Pharma, Inc.
A senior executive or director joined, left, or changed roles. An 8-K is the notice a US public company must file within four business days of a major event.
onconova.comAI Executive Summary
AI-powered analysis of 8-K filing content
On October 12, 2025, Traws Pharma's Compensation Committee granted stock options to five executive officers at an exercise price of $3.01 per share, with ten-year terms that vest in full after one year. The grants are routine equity compensation that ties executive pay to future share price performance and continued service.
Key Takeaways
The Compensation Committee granted 184,492 total options: 64,839 to CEO Iain Dukes, 32,406 each to CFO Charles Parker, CSO C. David Pauza, and CMO Robert Redfield, and 22,435 to COO Nikolay Savchuk.
The exercise price of $3.01 equals the closing price on October 10, 2025, the trading day before the grant, so the options were granted at the money.
2 more takeaways
Filing Overview
What This Means
Traws Pharma, Inc. filed with the SEC. Fundz turns 8-K material events into an alert with the right executive attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
4 screens from a live account. No signup.